这是一篇来自已证抗体库的有关人类 FOXP3的综述,是根据210篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合FOXP3 抗体。
FOXP3 同义词: AIID; DIETER; IPEX; JM2; PIDX; XPID; forkhead box protein P3; FOXP3delta7; immune dysregulation, polyendocrinopathy, enteropathy, X-linked; immunodeficiency, polyendocrinopathy, enteropathy, X-linked; scurfin

赛默飞世尔
大鼠 单克隆(PCH101)
  • 免疫组化-冰冻切片; 人类; 图 2c
赛默飞世尔 FOXP3抗体(eBiosciences, PCH101)被用于被用于免疫组化-冰冻切片在人类样品上 (图 2c). J Infect Dis (2018) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-冰冻切片; 人类; 图 1a
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于免疫组化-冰冻切片在人类样品上 (图 1a). J Exp Med (2018) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 小鼠; 图 7a
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在小鼠样品上 (图 7a). J Clin Invest (2018) ncbi
小鼠 单克隆(eBio7979)
  • 免疫组化-石蜡切片; 人类; 图 5b
赛默飞世尔 FOXP3抗体(eBioscience, 14-7979)被用于被用于免疫组化-石蜡切片在人类样品上 (图 5b). Int J Cancer (2018) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 1:100; 图 1a
赛默飞世尔 FOXP3抗体(eBioscience, 12-4776-42)被用于被用于流式细胞仪在人类样品上浓度为1:100 (图 1a). Nat Commun (2018) ncbi
兔 单克隆(5H10L18)
  • 免疫印迹; 人类; 1:1000; 图 4b
  • 免疫组化-石蜡切片; 小鼠; 1:100; 图 5a
  • 免疫印迹; 小鼠; 1:1000; 图 5c
赛默飞世尔 FOXP3抗体(Thermo Scientific, 700914)被用于被用于免疫印迹在人类样品上浓度为1:1000 (图 4b), 被用于免疫组化-石蜡切片在小鼠样品上浓度为1:100 (图 5a) 和 被用于免疫印迹在小鼠样品上浓度为1:1000 (图 5c). Br J Pharmacol (2018) ncbi
小鼠 单克隆(eBio7979)
  • 免疫印迹; 小鼠; 图 1d
赛默飞世尔 FOXP3抗体(eBioscience, eBio7979)被用于被用于免疫印迹在小鼠样品上 (图 1d). Sci Rep (2017) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 5a
赛默飞世尔 FOXP3抗体(ebioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 5a). Sci Rep (2017) ncbi
大鼠 单克隆(PCH101)
  • mass cytometry; 人类; 图 2a
赛默飞世尔 FOXP3抗体(eBiosciences, PCH101)被用于被用于mass cytometry在人类样品上 (图 2a). Proc Natl Acad Sci U S A (2017) ncbi
大鼠 单克隆(PCH101)
  • 免疫组化; 人类; 图 8a
赛默飞世尔 FOXP3抗体(ebioscience, PCH101)被用于被用于免疫组化在人类样品上 (图 8a). Front Immunol (2017) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 1f
赛默飞世尔 FOXP3抗体(ebioscience, 12-4776)被用于被用于流式细胞仪在人类样品上 (图 1f). J Immunol (2017) ncbi
小鼠 单克隆(150D/E4)
  • 染色质免疫沉淀 ; 小鼠; 图 2b
赛默飞世尔 FOXP3抗体(eBioscience, 14-4774-82)被用于被用于染色质免疫沉淀 在小鼠样品上 (图 2b). Cell Metab (2017) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 25-4777)被用于被用于流式细胞仪在人类样品上. J Immunol (2017) ncbi
小鼠 单克隆(150D/E4)
  • 免疫印迹; 人类; 图 2g
赛默飞世尔 FOXP3抗体(eBioscience, 150D/E4)被用于被用于免疫印迹在人类样品上 (图 2g). J Immunol (2017) ncbi
大鼠 单克隆(PCH101)
  • 免疫印迹; 人类; 图 2g
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于免疫印迹在人类样品上 (图 2g). J Immunol (2017) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 3a
赛默飞世尔 FOXP3抗体(Thermo Fisher Scientific, 17-4777)被用于被用于流式细胞仪在人类样品上 (图 3a). Cell Res (2017) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 6f
赛默飞世尔 FOXP3抗体(Thermo Fisher Scientific, 12-4776)被用于被用于流式细胞仪在人类样品上 (图 6f). Cell Res (2017) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 3b
赛默飞世尔 FOXP3抗体(eBiosciences, 236A/E7)被用于被用于流式细胞仪在人类样品上 (图 3b). J Immunol (2017) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 2
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 2). Clin Exp Immunol (2017) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 3b
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 3b). Med Princ Pract (2017) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 2e
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 2e). Am J Transplant (2017) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 1a
赛默飞世尔 FOXP3抗体(eBioscience, 48-4777-42)被用于被用于流式细胞仪在人类样品上 (图 1a). J Immunol Methods (2017) ncbi
小鼠 单克隆(150D/E4)
  • 流式细胞仪; 小鼠
赛默飞世尔 FOXP3抗体(eBioscience, 150D/E4)被用于被用于流式细胞仪在小鼠样品上. J Immunol (2016) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 图 6
  • 流式细胞仪; 人类; 图 1a
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上 (图 6) 和 被用于流式细胞仪在人类样品上 (图 1a). Int J Cancer (2017) ncbi
小鼠 单克隆(eBio7979)
  • 免疫印迹; 人类; 图 1a
赛默飞世尔 FOXP3抗体(eBioscience, eBio7979)被用于被用于免疫印迹在人类样品上 (图 1a). Oncotarget (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
  • 免疫细胞化学; 人类; 图 4b
赛默飞世尔 FOXP3抗体(eBiosciences, PCH101)被用于被用于流式细胞仪在人类样品上 和 被用于免疫细胞化学在人类样品上 (图 4b). J Exp Med (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. J Clin Invest (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 4b
赛默飞世尔 FOXP3抗体(NatuTec, PCH101)被用于被用于流式细胞仪在人类样品上 (图 4b). J Allergy Clin Immunol (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 2
赛默飞世尔 FOXP3抗体(eBioscience, 14-4777-82)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 2). J Transl Med (2016) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 人类; 1:150; 图 st1
赛默飞世尔 FOXP3抗体(ebioscience, 14-4777)被用于被用于免疫组化在人类样品上浓度为1:150 (图 st1). Oncoimmunology (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 s1
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 s1). Science (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 12-4776)被用于被用于流式细胞仪在人类样品上. Turk J Haematol (2016) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上. PLoS ONE (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 1:20; 表 2
赛默飞世尔 FOXP3抗体(eBioscience, 12-4776-42)被用于被用于流式细胞仪在人类样品上浓度为1:20 (表 2). Oncoimmunology (2016) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 1a
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上 (图 1a). PLoS ONE (2016) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 2c
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上 (图 2c). Am J Transplant (2016) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 4
赛默飞世尔 FOXP3抗体(eBiosciences, 12-4777-42)被用于被用于流式细胞仪在人类样品上 (图 4). J Clin Invest (2016) ncbi
小鼠 单克隆(150D/E4)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1
赛默飞世尔 FOXP3抗体(Ebioscience, 150D/E4)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 1). PLoS ONE (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 3c
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 3c). Science (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 12-4776)被用于被用于流式细胞仪在人类样品上. Immunity (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 1a
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 1a). Medicine (Baltimore) (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 8a
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 8a). PLoS Pathog (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 4d
赛默飞世尔 FOXP3抗体(eBioscience, 12-4776-42)被用于被用于流式细胞仪在人类样品上 (图 4d). J Immunol (2016) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 3a
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上 (图 3a). Eur J Immunol (2016) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 猕猴; 图 5
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在猕猴样品上 (图 5). Clin Exp Immunol (2016) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上. Nat Immunol (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-冰冻切片; 人类; 1:100; 图 1
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于免疫组化-冰冻切片在人类样品上浓度为1:100 (图 1). Nat Commun (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 4
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 4). Haematologica (2016) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 1). Medicine (Baltimore) (2015) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 8
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上 (图 8). J Clin Invest (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBiosciences, PCH101)被用于被用于流式细胞仪在人类样品上. Respir Res (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫细胞化学; 猪
  • 免疫组化; 猪; 1:50
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于免疫细胞化学在猪样品上 和 被用于免疫组化在猪样品上浓度为1:50. Vaccine (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上. Immunology (2015) ncbi
大鼠 单克隆(PCH101)
  • 免疫组化; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于免疫组化在人类样品上. World J Urol (2016) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, clone PCH101)被用于被用于流式细胞仪在人类样品上. Clin Vaccine Immunol (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 2b
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 2b). Retrovirology (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 st1
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 st1). Infect Immun (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 1 ul/test
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上浓度为1 ul/test. J Immunol Methods (2015) ncbi
小鼠 单克隆(150D/E4)
  • 流式细胞仪; 小鼠; 图 3
赛默飞世尔 FOXP3抗体(eBioscience, 150D/E4)被用于被用于流式细胞仪在小鼠样品上 (图 3). PLoS ONE (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 6
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 6). Cancer Immunol Res (2015) ncbi
小鼠 单克隆(eBio7979)
  • 免疫印迹; 小鼠; 1:500; 图 5,6
赛默飞世尔 FOXP3抗体(eBioscience, eBio7979)被用于被用于免疫印迹在小鼠样品上浓度为1:500 (图 5,6). Nat Commun (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 2
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 2). Cell Res (2015) ncbi
小鼠 单克隆(150D/E4)
  • 流式细胞仪; 大鼠; 图 1
赛默飞世尔 FOXP3抗体(eBiosciences, 150D/E4)被用于被用于流式细胞仪在大鼠样品上 (图 1). Mol Vis (2014) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 4
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 4). Nat Immunol (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 2
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 2). Mol Med Rep (2015) ncbi
小鼠 单克隆(eBio7979)
  • 免疫印迹; 小鼠
赛默飞世尔 FOXP3抗体(eBiosciences, eBio7979)被用于被用于免疫印迹在小鼠样品上. Nature (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBiosciences, PCH101)被用于被用于流式细胞仪在人类样品上. J Neuroimmunol (2014) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上. Hum Immunol (2014) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. Hum Immunol (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. J Immunol (2015) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上. J Immunol (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(e-Bioscience, PCH101)被用于被用于流式细胞仪在人类样品上. Nat Commun (2014) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. Nat Immunol (2015) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上. PLoS ONE (2014) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 5
赛默飞世尔 FOXP3抗体(e-Bioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 5). Clin Cancer Res (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. J Immunol (2014) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上. J Immunol (2014) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 14-4777-82)被用于被用于免疫组化-石蜡切片在人类样品上. J Immunol (2014) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 3a
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 3a). Eur J Immunol (2014) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 1
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 1). Immunology (2015) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. PLoS ONE (2014) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. Blood (2014) ncbi
大鼠 单克隆(PCH101)
  • 免疫细胞化学; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于免疫细胞化学在人类样品上. Eur J Immunol (2014) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上. PLoS ONE (2014) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
  • 免疫细胞化学; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 和 被用于免疫细胞化学在人类样品上. Mol Oncol (2014) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, clone 236A/E7)被用于被用于流式细胞仪在人类样品上. Mol Ther (2014) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 236-A/E7)被用于被用于流式细胞仪在人类样品上. Cancer Res (2014) ncbi
大鼠 单克隆(PCH101)
  • 免疫细胞化学; 人类; 1:200
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于免疫细胞化学在人类样品上浓度为1:200. J Crohns Colitis (2014) ncbi
小鼠 单克隆(eBio7979)
  • 免疫组化-石蜡切片; 羊; 1:250
赛默飞世尔 FOXP3抗体(eBioscience, 14-7979-82)被用于被用于免疫组化-石蜡切片在羊样品上浓度为1:250. Am J Physiol Gastrointest Liver Physiol (2014) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; African green monkey; 1:20; 图 s6
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在African green monkey样品上浓度为1:20 (图 s6). Nat Med (2013) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 2b
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 2b). AIDS Res Hum Retroviruses (2013) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 1:50; 图 1
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上浓度为1:50 (图 1). PLoS ONE (2012) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 1
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 1). Cell Immunol (2012) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 3a
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 3a). N Engl J Med (2011) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 1a
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 1a). J Virol (2011) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 人类; 1:1600
赛默飞世尔 FOXP3抗体(eBioscience, 144-777)被用于被用于免疫组化在人类样品上浓度为1:1600. PLoS ONE (2011) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 S5D
赛默飞世尔 FOXP3抗体(eBioscience, 15-4776-42)被用于被用于流式细胞仪在人类样品上 (图 S5D). Proc Natl Acad Sci U S A (2012) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 人类; 1:40; 图 S5B
赛默飞世尔 FOXP3抗体(eBioscience, 14-4777-82)被用于被用于免疫组化在人类样品上浓度为1:40 (图 S5B). Proc Natl Acad Sci U S A (2012) ncbi
小鼠 单克隆(eBio7979)
  • 免疫组化-石蜡切片; 人类; 1:50; 表 2
赛默飞世尔 FOXP3抗体(eBioscience, eBio7979)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (表 2). Breast Cancer (Auckl) (2011) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 大鼠; 50 ug/ml; 表 2
赛默飞世尔 FOXP3抗体(eBioscience, 236A)被用于被用于流式细胞仪在大鼠样品上浓度为50 ug/ml (表 2). Arthritis Res Ther (2011) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 s1
赛默飞世尔 FOXP3抗体(eBioscience, (clone PCH101))被用于被用于流式细胞仪在人类样品上 (图 s1). Blood (2010) ncbi
大鼠 单克隆(PCH101)
  • 免疫组化; 人类; 1:200; 图 2
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于免疫组化在人类样品上浓度为1:200 (图 2). J Clin Endocrinol Metab (2010) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 小鼠; 图 3
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在小鼠样品上 (图 3). Blood (2010) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 1
赛默飞世尔 FOXP3抗体(eBioscience, PCH 101)被用于被用于流式细胞仪在人类样品上 (图 1). J Immunol (2010) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. Arthritis Rheum (2010) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. PLoS Biol (2010) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 4
赛默飞世尔 FOXP3抗体(eBiosciences, PCH101)被用于被用于流式细胞仪在人类样品上 (图 4). Br J Dermatol (2010) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 1
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 1). Blood (2009) ncbi
小鼠 单克隆(eBio7979)
  • 免疫印迹; 小鼠; 2 ug/ml; 图 7
赛默飞世尔 FOXP3抗体(eBioscience, eBio7979)被用于被用于免疫印迹在小鼠样品上浓度为2 ug/ml (图 7). J Immunol (2009) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 人类; 1:100; 图 8
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于免疫组化在人类样品上浓度为1:100 (图 8). J Immunol (2009) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. J Immunol (2009) ncbi
小鼠 单克隆(eBio7979)
  • 免疫组化; 人类; 1:50; 图 2
赛默飞世尔 FOXP3抗体(eBioscience, 14-7979)被用于被用于免疫组化在人类样品上浓度为1:50 (图 2). PLoS ONE (2008) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 表 1
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (表 1). Clin Dev Immunol (2008) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 4a
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 4a). Blood (2008) ncbi
大鼠 单克隆(PCH101)
  • 免疫印迹; 人类; 2 ug/ml
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于免疫印迹在人类样品上浓度为2 ug/ml. Cancer Res (2008) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上. Cancer Res (2008) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; African green monkey
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在African green monkey样品上. Exp Biol Med (Maywood) (2007) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 4
  • 免疫组化; 人类; 图 6
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于流式细胞仪在人类样品上 (图 4) 和 被用于免疫组化在人类样品上 (图 6). J Immunol (2007) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 9A
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 9A). Int Immunol (2007) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. Gastroenterology (2007) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类; 图 5
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上 (图 5). Blood (2007) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. Inflamm Bowel Dis (2007) ncbi
大鼠 单克隆(PCH101)
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, PCH101)被用于被用于流式细胞仪在人类样品上. J Immunol (2006) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-冰冻切片; 人类
  • 流式细胞仪; 人类
赛默飞世尔 FOXP3抗体(eBioscience, 236A/E7)被用于被用于免疫组化-冰冻切片在人类样品上 和 被用于流式细胞仪在人类样品上. J Immunol (2006) ncbi
艾博抗(上海)贸易有限公司
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 图 1a
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 20034)被用于被用于免疫组化-石蜡切片在人类样品上 (图 1a). Sci Rep (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 2k
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 2k). Arch Dermatol Res (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 小鼠; 图 s3b
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫组化在小鼠样品上 (图 s3b). FASEB J (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 图 2c
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上 (图 2c). Proc Natl Acad Sci U S A (2017) ncbi
小鼠 单克隆(mAbcam 22510)
  • 免疫组化-石蜡切片; 人类; 表 1
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab22510)被用于被用于免疫组化-石蜡切片在人类样品上 (表 1). Cell (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 人类; 1:50; 图 2c
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫组化在人类样品上浓度为1:50 (图 2c). Cell Res (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫印迹; 人类; 图 3D
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫印迹在人类样品上 (图 3D). Int J Mol Sci (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-冰冻切片; 人类; 图 4b
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-冰冻切片在人类样品上 (图 4b). Am J Transplant (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 人类; 图 1c
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫组化在人类样品上 (图 1c). Genome Biol (2016) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 2c
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 2c). Cancer Immunol Immunother (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 20 ug/ml; 图 3a
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫组化-石蜡切片在人类样品上浓度为20 ug/ml (图 3a). J Immunol Res (2016) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 图 1
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上 (图 1). Cancer Sci (2016) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 表 3
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上 (表 3). J Eur Acad Dermatol Venereol (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 图 2b
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上 (图 2b). J Allergy Clin Immunol (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 小鼠; 图 6b
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化在小鼠样品上 (图 6b). Clin Cancer Res (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 小鼠; 1:500; 图 3
艾博抗(上海)贸易有限公司 FOXP3抗体(abcam, ab20034)被用于被用于免疫组化-石蜡切片在小鼠样品上浓度为1:500 (图 3). Mol Med Rep (2016) ncbi
小鼠 单克隆(mAbcam 22510)
  • 免疫组化-石蜡切片; 人类; 17.0 ug/ml; 图 1F
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab22510)被用于被用于免疫组化-石蜡切片在人类样品上浓度为17.0 ug/ml (图 1F). PLoS ONE (2016) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 图 1
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫组化-石蜡切片在人类样品上 (图 1). Oncotarget (2016) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 3
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 3). Mod Pathol (2016) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 图 1
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, Ab20034)被用于被用于免疫组化-石蜡切片在人类样品上 (图 1). Head Neck (2016) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 人类; 1:50; 表 2
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫组化在人类样品上浓度为1:50 (表 2). Hematol Oncol (2017) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 1:100
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. PLoS ONE (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 图 2
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, AB20034)被用于被用于免疫组化-石蜡切片在人类样品上 (图 2). J Immunother Cancer (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上. Laryngoscope (2016) ncbi
小鼠 单克隆(mAbcam 22510)
  • 免疫组化-石蜡切片; 人类; 20 ug/ml; 图 3b
  • 免疫印迹; 人类; 图 3f
艾博抗(上海)贸易有限公司 FOXP3抗体(abcam, ab22510)被用于被用于免疫组化-石蜡切片在人类样品上浓度为20 ug/ml (图 3b) 和 被用于免疫印迹在人类样品上 (图 3f). PLoS ONE (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 人类; 图 5
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫组化在人类样品上 (图 5). Oncoimmunology (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫组化-石蜡切片在人类样品上. Cancer Immunol Immunother (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 1:800
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:800. J Dermatol Sci (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 图 St1A
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫组化-石蜡切片在人类样品上 (图 St1A). Breast Cancer Res Treat (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 人类
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化在人类样品上. Dis Markers (2014) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 1:60
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:60. World J Gastroenterol (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 1:180; 图 4
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:180 (图 4). PLoS ONE (2014) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 图 1
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上 (图 1). Cancer Discov (2015) ncbi
小鼠 单克隆(mAbcam 22510)
  • 免疫印迹; 人类; 图 1a
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab22510)被用于被用于免疫印迹在人类样品上 (图 1a). Liver Int (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 人类; 图 1c
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, ab20034)被用于被用于免疫组化在人类样品上 (图 1c). Liver Int (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类; 1:100
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236 A/E7)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Br J Dermatol (2015) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化; 人类; 1:100
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化在人类样品上浓度为1:100. PLoS Pathog (2014) ncbi
小鼠 单克隆(236a/E7)
  • 免疫组化-石蜡切片; 人类
艾博抗(上海)贸易有限公司 FOXP3抗体(Abcam, 236A/E7)被用于被用于免疫组化-石蜡切片在人类样品上. Cancer (2011) ncbi
BioLegend
小鼠 单克隆(259D)
  • 流式细胞仪; 人类; 图 5a
BioLegend FOXP3抗体(BioLegend, 259D)被用于被用于流式细胞仪在人类样品上 (图 5a). Front Immunol (2018) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 人类; 图 3c
BioLegend FOXP3抗体(Biolegend, 320013)被用于被用于流式细胞仪在人类样品上 (图 3c). Biosci Rep (2018) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 图 1
BioLegend FOXP3抗体(BioLegend, 206D)被用于被用于流式细胞仪在人类样品上 (图 1). Am J Trop Med Hyg (2018) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 小鼠; 图 s2a
BioLegend FOXP3抗体(BioLegend, 150D)被用于被用于流式细胞仪在小鼠样品上 (图 s2a). J Clin Invest (2018) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 图 3b
  • 免疫组化; 人类; 图 3a
BioLegend FOXP3抗体(Biolegend, 206D)被用于被用于流式细胞仪在人类样品上 (图 3b) 和 被用于免疫组化在人类样品上 (图 3a). J Immunol (2018) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 图 4d
BioLegend FOXP3抗体(BioLegend, 206D)被用于被用于流式细胞仪在人类样品上 (图 4d). Proc Natl Acad Sci U S A (2017) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 小鼠; 1:50; 图 5b
BioLegend FOXP3抗体(Biolegend, 150D)被用于被用于流式细胞仪在小鼠样品上浓度为1:50 (图 5b). Nat Commun (2017) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 小鼠; 图 4c
BioLegend FOXP3抗体(BioLegend, 150D)被用于被用于流式细胞仪在小鼠样品上 (图 4c). JCI Insight (2017) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 图 4d
BioLegend FOXP3抗体(Biolegend, 320114)被用于被用于流式细胞仪在人类样品上 (图 4d). Front Immunol (2016) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 图 1b
BioLegend FOXP3抗体(BioLegend, 206D)被用于被用于流式细胞仪在人类样品上 (图 1b). Cell Death Dis (2016) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 图 2b
BioLegend FOXP3抗体(Biolegend, 206D)被用于被用于流式细胞仪在人类样品上 (图 2b). Cancer Res (2016) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 图 s2
BioLegend FOXP3抗体(Biolegend, 206D)被用于被用于流式细胞仪在人类样品上 (图 s2). PLoS Pathog (2016) ncbi
小鼠 单克隆(206D)
  • 免疫组化-石蜡切片; 人类; 5 ug/ml; 表 2
BioLegend FOXP3抗体(Biolegend, 320102)被用于被用于免疫组化-石蜡切片在人类样品上浓度为5 ug/ml (表 2). Pathology (2016) ncbi
小鼠 单克隆(259D)
  • 流式细胞仪; 人类; 1:20; 图 st2
BioLegend FOXP3抗体(Biolegend, 320216)被用于被用于流式细胞仪在人类样品上浓度为1:20 (图 st2). Nat Commun (2016) ncbi
小鼠 单克隆(150D)
  • 染色质免疫沉淀 ; 小鼠; 图 4
BioLegend FOXP3抗体(Biolegend, 150D)被用于被用于染色质免疫沉淀 在小鼠样品上 (图 4). Nat Immunol (2016) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 小鼠; 图 5d
BioLegend FOXP3抗体(BioLegend, 150D)被用于被用于流式细胞仪在小鼠样品上 (图 5d). Gastroenterology (2016) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 图 6b
BioLegend FOXP3抗体(BioLegend, 206D)被用于被用于流式细胞仪在人类样品上 (图 6b). J Allergy Clin Immunol (2016) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 小鼠; 图 6
BioLegend FOXP3抗体(BioLegend, 150D)被用于被用于流式细胞仪在小鼠样品上 (图 6). J Transl Med (2016) ncbi
小鼠 单克隆(150D)
  • 免疫印迹; 小鼠; 1:500; 图 4
BioLegend FOXP3抗体(Biolegend, 150D)被用于被用于免疫印迹在小鼠样品上浓度为1:500 (图 4). PLoS ONE (2015) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 人类
BioLegend FOXP3抗体(Biolegend, 320014)被用于被用于流式细胞仪在人类样品上. Mol Oncol (2015) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 小鼠; 图 2
BioLegend FOXP3抗体(BioLegend, 320014)被用于被用于流式细胞仪在小鼠样品上 (图 2). Oncoimmunology (2014) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 图 6
BioLegend FOXP3抗体(BioLegend, 206D)被用于被用于流式细胞仪在人类样品上 (图 6). Bone Marrow Transplant (2015) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 表 s1
BioLegend FOXP3抗体(Biolegend, 206D)被用于被用于流式细胞仪在人类样品上 (表 s1). PLoS ONE (2015) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 图 6
BioLegend FOXP3抗体(BioLegend, 206D)被用于被用于流式细胞仪在人类样品上 (图 6). PLoS ONE (2015) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 人类; 图 5
BioLegend FOXP3抗体(Biolegend, 150D)被用于被用于流式细胞仪在人类样品上 (图 5). J Cell Mol Med (2015) ncbi
小鼠 单克隆(206D)
  • 免疫组化; 人类; 图 2
BioLegend FOXP3抗体(320102, 320102)被用于被用于免疫组化在人类样品上 (图 2). Clin Cancer Res (2015) ncbi
小鼠 单克隆(259D)
  • 流式细胞仪; 小鼠; 图 8
BioLegend FOXP3抗体(BioLegend, 320212)被用于被用于流式细胞仪在小鼠样品上 (图 8). J Immunol (2015) ncbi
小鼠 单克隆(206D)
  • 流式细胞仪; 人类; 图 1
BioLegend FOXP3抗体(BioLegend, 206D)被用于被用于流式细胞仪在人类样品上 (图 1). J Immunol (2015) ncbi
兔 多克隆(Poly6238)
BioLegend FOXP3抗体(Biolegend, 623801)被用于. Neuro Oncol (2015) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 小鼠
BioLegend FOXP3抗体(BioLegend, 150D)被用于被用于流式细胞仪在小鼠样品上. J Immunol (2014) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 大鼠; 图 7
BioLegend FOXP3抗体(BioLegend, 150D)被用于被用于流式细胞仪在大鼠样品上 (图 7). Eur J Immunol (2015) ncbi
小鼠 单克隆(206D)
BioLegend FOXP3抗体(Biolegend, 206D)被用于. PLoS ONE (2014) ncbi
小鼠 单克隆(206D)
BioLegend FOXP3抗体(BioLegend, 320102)被用于. Cancer Immunol Res (2014) ncbi
小鼠 单克隆(150D)
BioLegend FOXP3抗体(BioLegend, 150D)被用于. Nat Commun (2014) ncbi
小鼠 单克隆(150D)
  • 流式细胞仪; 小鼠
BioLegend FOXP3抗体(Biolegend, 320013)被用于被用于流式细胞仪在小鼠样品上. Exp Parasitol (2014) ncbi
小鼠 单克隆(150D)
  • 免疫细胞化学; 人类; 1:50
BioLegend FOXP3抗体(BioLegend, 150D)被用于被用于免疫细胞化学在人类样品上浓度为1:50. Nephrology (Carlton) (2014) ncbi
北京傲锐东源
兔 多克隆(polyclonal)
  • 免疫印迹; 人类; 图 1i
北京傲锐东源 FOXP3抗体(Origene, TA319911)被用于被用于免疫印迹在人类样品上 (图 1i). Oncotarget (2016) ncbi
Novus Biologicals
兔 多克隆
  • 免疫组化-石蜡切片; 人类
  • 免疫组化-石蜡切片; 小鼠; 图 3c
Novus Biologicals FOXP3抗体(Novus Biologicals, NB100-39002)被用于被用于免疫组化-石蜡切片在人类样品上 和 被用于免疫组化-石蜡切片在小鼠样品上 (图 3c). Nature (2015) ncbi
圣克鲁斯生物技术
小鼠 单克隆(F-9)
  • 免疫组化-石蜡切片; 小鼠; 表 1
圣克鲁斯生物技术 FOXP3抗体(Santa Cruz, sc166212)被用于被用于免疫组化-石蜡切片在小鼠样品上 (表 1). Methods Mol Biol (2015) ncbi
Tonbo Biosciences
小鼠 单克隆(3G3)
  • 流式细胞仪; 小鼠; 图 4b
Tonbo Biosciences FOXP3抗体(Tonbo, 3G3)被用于被用于流式细胞仪在小鼠样品上 (图 4b). Nutrients (2018) ncbi
小鼠 单克隆(3G3)
  • 流式细胞仪; 小鼠; 图 2e
Tonbo Biosciences FOXP3抗体(TONBO Bioscience, 3G3)被用于被用于流式细胞仪在小鼠样品上 (图 2e). J Exp Med (2016) ncbi
赛信通(上海)生物试剂有限公司
兔 单克隆(D2W8E)
  • 免疫细胞化学; 人类; 1:100; 图 s6c
赛信通(上海)生物试剂有限公司 FOXP3抗体(Cell Signaling, D2W8E)被用于被用于免疫细胞化学在人类样品上浓度为1:100 (图 s6c). J Immunother Cancer (2017) ncbi
碧迪BD
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 图 1b
碧迪BD FOXP3抗体(BD Biosciences, 259D/C7)被用于被用于流式细胞仪在人类样品上 (图 1b). J Exp Med (2018) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 图 s2d
碧迪BD FOXP3抗体(BD, 259D/C7)被用于被用于流式细胞仪在人类样品上 (图 s2d). Nature (2017) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类
碧迪BD FOXP3抗体(BD BIOSCIENCES, 236A/E7)被用于被用于流式细胞仪在人类样品上. Nature (2017) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 图 s1c
碧迪BD FOXP3抗体(BD Biosciences, 259D/C7)被用于被用于流式细胞仪在人类样品上 (图 s1c). Proc Natl Acad Sci U S A (2016) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 1
碧迪BD FOXP3抗体(BD, 561493)被用于被用于流式细胞仪在人类样品上 (图 1). Oncoimmunology (2016) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 图 s7
碧迪BD FOXP3抗体(BD Biosciences, 259D)被用于被用于流式细胞仪在人类样品上 (图 s7). Proc Natl Acad Sci U S A (2016) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 表 3
碧迪BD FOXP3抗体(BD Pharmingen, 259D/C7)被用于被用于流式细胞仪在人类样品上 (表 3). Brain Behav (2016) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类
碧迪BD FOXP3抗体(BD, 259D/C7)被用于被用于流式细胞仪在人类样品上. J Exp Med (2016) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 1:100; 图 4
碧迪BD FOXP3抗体(BD Biosciences, 560045)被用于被用于流式细胞仪在人类样品上浓度为1:100 (图 4). Clin Cancer Res (2016) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 图 st1
碧迪BD FOXP3抗体(BD, 560046)被用于被用于流式细胞仪在人类样品上 (图 st1). Exp Cell Res (2016) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 图 4b
碧迪BD FOXP3抗体(BD, 560046)被用于被用于流式细胞仪在人类样品上 (图 4b). Front Immunol (2015) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 1:25; 表 1
碧迪BD FOXP3抗体(BD Horizon, 562421)被用于被用于流式细胞仪在人类样品上浓度为1:25 (表 1). PLoS ONE (2015) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 图 2b
碧迪BD FOXP3抗体(BD PharMingen, 560046)被用于被用于流式细胞仪在人类样品上 (图 2b). PLoS ONE (2015) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 s1
碧迪BD FOXP3抗体(BD Pharmingen, 561181)被用于被用于流式细胞仪在人类样品上 (图 s1). Stem Cell Reports (2015) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 1b,1c,1e,1f
碧迪BD FOXP3抗体(BD, 561493)被用于被用于流式细胞仪在人类样品上 (图 1b,1c,1e,1f). PLoS Pathog (2015) ncbi
小鼠 单克隆(236a/E7)
  • 流式细胞仪; 人类; 图 2
碧迪BD FOXP3抗体(BD Biosciences, 236A/E7)被用于被用于流式细胞仪在人类样品上 (图 2). J Autoimmun (2015) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 图 1
碧迪BD FOXP3抗体(BD Biosciences, 259D)被用于被用于流式细胞仪在人类样品上 (图 1). Diabetes (2015) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 图 1g
碧迪BD FOXP3抗体(BD Bioscience, 560459)被用于被用于流式细胞仪在人类样品上 (图 1g). Immunol Res (2015) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类
碧迪BD FOXP3抗体(BD Biosciences, 259D/C7)被用于被用于流式细胞仪在人类样品上. J Immunol (2015) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类
碧迪BD FOXP3抗体(BD, 259D/C7)被用于被用于流式细胞仪在人类样品上. J Immunol (2015) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类
碧迪BD FOXP3抗体(BD Biosciences, 259D/C7)被用于被用于流式细胞仪在人类样品上. PLoS ONE (2014) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 图 1
碧迪BD FOXP3抗体(BD Biosciences, 259D/C7)被用于被用于流式细胞仪在人类样品上 (图 1). Cancer Discov (2015) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类; 图 1b
碧迪BD FOXP3抗体(BD, 259D/C7)被用于被用于流式细胞仪在人类样品上 (图 1b). Eur J Immunol (2014) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类
碧迪BD FOXP3抗体(BD Pharmingen, 259D/C7)被用于被用于流式细胞仪在人类样品上. Immunol Cell Biol (2014) ncbi
小鼠 单克隆(259D/C7)
  • 流式细胞仪; 人类
碧迪BD FOXP3抗体(BD Biosciences, 259D/C7)被用于被用于流式细胞仪在人类样品上. PLoS Pathog (2014) ncbi
文章列表
  1. Richardson J, Armbruster N, Günter M, Henes J, Autenrieth S. Staphylococcus aureus PSM Peptides Modulate Human Monocyte-Derived Dendritic Cells to Prime Regulatory T Cells. Front Immunol. 2018;9:2603 pubmed 出版商
  2. Masuda J, Umemura C, Yokozawa M, Yamauchi K, Seko T, Yamashita M, et al. Dietary Supplementation of Selenoneine-Containing Tuna Dark Muscle Extract Effectively Reduces Pathology of Experimental Colorectal Cancers in Mice. Nutrients. 2018;10: pubmed 出版商
  3. Patel N, Vukmanovic Stejic M, Suárez Fariñas M, Chambers E, Sandhu D, Fuentes Duculan J, et al. Impact of Zostavax Vaccination on T-Cell Accumulation and Cutaneous Gene Expression in the Skin of Older Humans After Varicella Zoster Virus Antigen-Specific Challenge. J Infect Dis. 2018;218:S88-S98 pubmed 出版商
  4. Zhao S, Ding J, Wang S, Li C, Guo P, Zhang M, et al. Decreased expression of circulating Aire and increased Tfh/Tfr cells in myasthenia gravis patients. Biosci Rep. 2018;38: pubmed 出版商
  5. Sayin I, Radtke A, Vella L, Jin W, Wherry E, Buggert M, et al. Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med. 2018;215:1531-1542 pubmed 出版商
  6. Ondigo B, Ndombi E, Nicholson S, Oguso J, Carter J, Kittur N, et al. Functional Studies of T Regulatory Lymphocytes in Human Schistosomiasis in Western Kenya. Am J Trop Med Hyg. 2018;98:1770-1781 pubmed 出版商
  7. Varelias A, Bunting M, Ormerod K, Koyama M, Olver S, Straube J, et al. Recipient mucosal-associated invariant T cells control GVHD within the colon. J Clin Invest. 2018;128:1919-1936 pubmed 出版商
  8. Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine T, et al. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest. 2018;128:2487-2499 pubmed 出版商
  9. Qu S, Xue H, Dong X, Lin D, Wu R, Nabavi N, et al. Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. Int J Cancer. 2018;143:419-429 pubmed 出版商
  10. Hsieh W, Hsu T, Chang Y, Lai M. IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells. Nat Commun. 2018;9:463 pubmed 出版商
  11. Lu Y, Kim N, Jiang Y, Zhang H, Zheng D, Zhu F, et al. Cambogin suppresses dextran sulphate sodium-induced colitis by enhancing Treg cell stability and function. Br J Pharmacol. 2018;175:1085-1099 pubmed 出版商
  12. Amodio D, Cotugno N, Macchiarulo G, Rocca S, Dimopoulos Y, Castrucci M, et al. Quantitative Multiplexed Imaging Analysis Reveals a Strong Association between Immunogen-Specific B Cell Responses and Tonsillar Germinal Center Immune Dynamics in Children after Influenza Vaccination. J Immunol. 2018;200:538-550 pubmed 出版商
  13. Mailer R, Gisterå A, Polyzos K, Ketelhuth D, Hansson G. Hypercholesterolemia Enhances T Cell Receptor Signaling and Increases the Regulatory T Cell Population. Sci Rep. 2017;7:15655 pubmed 出版商
  14. Blom S, Paavolainen L, Bychkov D, Turkki R, Mäki Teeri P, Hemmes A, et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. Sci Rep. 2017;7:15580 pubmed 出版商
  15. Carvajal Hausdorf D, Mani N, Velcheti V, Schalper K, Rimm D. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. J Immunother Cancer. 2017;5:81 pubmed 出版商
  16. Matsuyama K, Mizutani Y, Takahashi T, Shu E, Kanoh H, Miyazaki T, et al. Enhanced dendritic cells and regulatory T cells in the dermis of porokeratosis. Arch Dermatol Res. 2017;309:749-756 pubmed 出版商
  17. Liaskou E, Jeffery L, Chanouzas D, Soskic B, Seldin M, Harper L, et al. Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. Sci Rep. 2017;7:7652 pubmed 出版商
  18. Funken D, Ishikawa Ankerhold H, Uhl B, Lerchenberger M, Rentsch M, Mayr D, et al. In situ targeting of dendritic cells sets tolerogenic environment and ameliorates CD4+ T-cell response in the postischemic liver. FASEB J. 2017;31:4796-4808 pubmed 出版商
  19. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed 出版商
  20. Dias J, Leeansyah E, Sandberg J. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc Natl Acad Sci U S A. 2017;114:E5434-E5443 pubmed 出版商
  21. Zheng C, Zheng L, Yoo J, Guo H, Zhang Y, Guo X, et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017;169:1342-1356.e16 pubmed 出版商
  22. Garcia Hernandez M, Uribe Uribe N, Espinosa González R, Kast W, Khader S, Rangel Moreno J. A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression. Front Immunol. 2017;8:563 pubmed 出版商
  23. Hasan Z, Koizumi S, Sasaki D, Yamada H, Arakaki N, Fujihara Y, et al. JunB is essential for IL-23-dependent pathogenicity of Th17 cells. Nat Commun. 2017;8:15628 pubmed 出版商
  24. Ventura E, Weller M, Burghardt I. Cutting Edge: ERK1 Mediates the Autocrine Positive Feedback Loop of TGF-? and Furin in Glioma-Initiating Cells. J Immunol. 2017;198:4569-4574 pubmed 出版商
  25. Angelin A, Gil de Gómez L, Dahiya S, Jiao J, Guo L, Levine M, et al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. Cell Metab. 2017;25:1282-1293.e7 pubmed 出版商
  26. Huang A, Postow M, Orlowski R, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60-65 pubmed 出版商
  27. Zanin Zhorov A, Weiss J, Trzeciak A, Chen W, Zhang J, Nyuydzefe M, et al. Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. J Immunol. 2017;198:3809-3814 pubmed 出版商
  28. Melis D, Carbone F, Minopoli G, La Rocca C, Perna F, De Rosa V, et al. Cutting Edge: Increased Autoimmunity Risk in Glycogen Storage Disease Type 1b Is Associated with a Reduced Engagement of Glycolysis in T Cells and an Impaired Regulatory T Cell Function. J Immunol. 2017;198:3803-3808 pubmed 出版商
  29. Su S, Liao J, Liu J, Huang D, He C, Chen F, et al. Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Res. 2017;27:461-482 pubmed 出版商
  30. Szabo P, Goswami A, Mazzuca D, Kim K, O Gorman D, Hess D, et al. Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology. J Immunol. 2017;198:2805-2818 pubmed 出版商
  31. Jeffery H, Jeffery L, Lutz P, Corrigan M, Webb G, Hirschfield G, et al. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol. 2017;188:394-411 pubmed 出版商
  32. Rao D, Gurish M, Marshall J, Slowikowski K, Fonseka C, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542:110-114 pubmed 出版商
  33. Kempińska Podhorodecka A, Milkiewicz M, Wasik U, Ligocka J, Zawadzki M, Krawczyk M, et al. Decreased Expression of Vitamin D Receptor Affects an Immune Response in Primary Biliary Cholangitis via the VDR-miRNA155-SOCS1 Pathway. Int J Mol Sci. 2017;18: pubmed 出版商
  34. Yanagita T, Murata Y, Tanaka D, Motegi S, Arai E, Daniwijaya E, et al. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight. 2017;2:e89140 pubmed 出版商
  35. Kim J, Kwon C, Joh J, Sinn D, Choi G, Park J, et al. Differences in Peripheral Blood Lymphocytes between Brand-Name and Generic Tacrolimus Used in Stable Liver Transplant Recipients. Med Princ Pract. 2017;26:221-228 pubmed 出版商
  36. Boardman D, Philippeos C, Fruhwirth G, Ibrahim M, Hannen R, Cooper D, et al. Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. Am J Transplant. 2017;17:931-943 pubmed 出版商
  37. Lévy R, Okada S, Béziat V, Moriya K, Liu C, Chai L, et al. Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc Natl Acad Sci U S A. 2016;113:E8277-E8285 pubmed 出版商
  38. Zhu H, Hu F, Sun X, Zhang X, Zhu L, Liu X, et al. CD16+ Monocyte Subset Was Enriched and Functionally Exacerbated in Driving T-Cell Activation and B-Cell Response in Systemic Lupus Erythematosus. Front Immunol. 2016;7:512 pubmed
  39. Wei C, Mei J, Tang L, Liu Y, Li D, Li M, et al. 1-Methyl-tryptophan attenuates regulatory T cells differentiation due to the inhibition of estrogen-IDO1-MRC2 axis in endometriosis. Cell Death Dis. 2016;7:e2489 pubmed 出版商
  40. Senbabaoglu Y, Gejman R, Winer A, Liu M, Van Allen E, de Velasco G, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016;17:231 pubmed
  41. Sundara Y, Kostine M, Cleven A, Bovee J, Schilham M, Cleton Jansen A. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2017;66:119-128 pubmed 出版商
  42. Li J, Shayan G, Avery L, Jie H, Gildener Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5:e1200778 pubmed
  43. Weingartner E, Courneya J, Keegan A, Golding A. A novel method for assaying human regulatory T cell direct suppression of B cell effector function. J Immunol Methods. 2017;441:1-7 pubmed 出版商
  44. Shifrin N, Kissiov D, Ardolino M, Joncker N, Raulet D. Differential Role of Hematopoietic and Nonhematopoietic Cell Types in the Regulation of NK Cell Tolerance and Responsiveness. J Immunol. 2016;197:4127-4136 pubmed 出版商
  45. Peters C, Häsler R, Wesch D, Kabelitz D. Human Vδ2 T cells are a major source of interleukin-9. Proc Natl Acad Sci U S A. 2016;113:12520-12525 pubmed
  46. Dyer W, Tan J, Day T, Kiers L, Kiernan M, Yiannikas C, et al. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Brain Behav. 2016;6:e00516 pubmed
  47. Kaewkangsadan V, Verma C, Eremin J, Cowley G, Ilyas M, Eremin O. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res. 2016;2016:4757405 pubmed
  48. Nagase H, Takeoka T, Urakawa S, Morimoto Okazawa A, Kawashima A, Iwahori K, et al. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017;140:686-695 pubmed 出版商
  49. Ogiya R, Niikura N, Kumaki N, Bianchini G, Kitano S, Iwamoto T, et al. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci. 2016;107:1730-1735 pubmed 出版商
  50. Wang Y, Ma C, Ling Y, Bousfiha A, Camcioglu Y, Jacquot S, et al. Dual T cell- and B cell-intrinsic deficiency in humans with biallelic RLTPR mutations. J Exp Med. 2016;213:2413-2435 pubmed
  51. Klarquist J, Tobin K, Farhangi Oskuei P, Henning S, Fernandez M, Dellacecca E, et al. Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma. Cancer Res. 2016;76:6230-6240 pubmed
  52. Pachnio A, Ciáurriz M, Begum J, Lal N, Zuo J, Beggs A, et al. Cytomegalovirus Infection Leads to Development of High Frequencies of Cytotoxic Virus-Specific CD4+ T Cells Targeted to Vascular Endothelium. PLoS Pathog. 2016;12:e1005832 pubmed 出版商
  53. Javvadi L, Parachuru V, Milne T, Seymour G, Rich A. Regulatory T-cells and IL17A(+) cells infiltrate oral lichen planus lesions. Pathology. 2016;48:564-73 pubmed 出版商
  54. Jou Y, Tsai Y, Lin C, Tung C, Shen C, Tsai H, et al. Foxp3 enhances HIF-1α target gene expression in human bladder cancer through decreasing its ubiquitin-proteasomal degradation. Oncotarget. 2016;7:65403-65417 pubmed 出版商
  55. Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, et al. Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. J Exp Med. 2016;213:1881-900 pubmed 出版商
  56. Torrelo A, Noguera Morel L, Hernandez Martin A, Clemente D, Barja J, Buzon L, et al. Recurrent lipoatrophic panniculitis of children. J Eur Acad Dermatol Venereol. 2017;31:536-543 pubmed 出版商
  57. Cheng H, Gaddis D, Wu R, McSkimming C, Haynes L, Taylor A, et al. Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis. J Clin Invest. 2016;126:3236-46 pubmed 出版商
  58. Chen H, Händel N, Ngeow J, Muller J, Huhn M, Yang H, et al. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol. 2017;139:607-620.e15 pubmed 出版商
  59. Miyan M, Schmidt Mende J, Kiessling R, Poschke I, de Boniface J. Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. J Transl Med. 2016;14:227 pubmed 出版商
  60. Baras A, Drake C, Liu J, Gandhi N, Kates M, Hoque M, et al. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology. 2016;5:e1134412 pubmed 出版商
  61. Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, et al. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clin Cancer Res. 2017;23:149-158 pubmed 出版商
  62. Orta Mascaró M, Consuegra Fernández M, Carreras E, Roncagalli R, Carreras Sureda A, Alvarez P, et al. CD6 modulates thymocyte selection and peripheral T cell homeostasis. J Exp Med. 2016;213:1387-97 pubmed 出版商
  63. Brinkman C, Iwami D, Hritzo M, Xiong Y, Ahmad S, Simon T, et al. Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. Nat Commun. 2016;7:12021 pubmed 出版商
  64. Gu L, Deng W, Sun X, Zhou H, Xu Q. Rapamycin ameliorates CCl4-induced liver fibrosis in mice through reciprocal regulation of the Th17/Treg cell balance. Mol Med Rep. 2016;14:1153-61 pubmed 出版商
  65. Chu H, Khosravi A, Kusumawardhani I, Kwon A, Vasconcelos A, Cunha L, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science. 2016;352:1116-20 pubmed 出版商
  66. Akyol Erikci A, Karagoz B, Bilgi O. Regulatory T Cells in Patients with Idiopathic Thrombocytopenic Purpura. Turk J Haematol. 2016;33:153-5 pubmed 出版商
  67. Zhang H, Prado K, Zhang K, Peek E, Lee J, Wang X, et al. Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance. Clin Cancer Res. 2016;22:5349-5361 pubmed
  68. Stikvoort A, Sundin M, Uzunel M, Gertow J, Sundberg B, Schaffer M, et al. Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?. PLoS ONE. 2016;11:e0154737 pubmed 出版商
  69. Cook A, McDonnell A, Lake R, Nowak A. Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology. 2016;5:e1066062 pubmed
  70. Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, et al. PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS ONE. 2016;11:e0153954 pubmed 出版商
  71. Goldstein J, Burlion A, Zaragoza B, Sendeyo K, Polansky J, Huehn J, et al. Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells Reveals a Very Dynamic Regulation of Foxp3 Expression. PLoS ONE. 2016;11:e0153682 pubmed 出版商
  72. Zwang N, Zhang R, Germana S, Fan M, Hastings W, Cao A, et al. Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways. Am J Transplant. 2016;16:2624-38 pubmed 出版商
  73. Chen C, Liu Y, Hua M, Li X, Ji C, Ma D. Neuropathy correlated with imbalanced Foxp3/IL-17 in bone marrow microenvironment of patients with acute myeloid leukemia. Oncotarget. 2016;7:24455-65 pubmed 出版商
  74. Macdonald K, Hoeppli R, Huang Q, Gillies J, Luciani D, Orban P, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126:1413-24 pubmed 出版商
  75. Apostolidis S, Rodríguez Rodríguez N, Suárez Fueyo A, Dioufa N, Ozcan E, Crispín J, et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat Immunol. 2016;17:556-64 pubmed 出版商
  76. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed 出版商
  77. Friedman K, Brodsky A, Lu S, Wood S, Gill A, Lombardo K, et al. Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Mod Pathol. 2016;29:528-41 pubmed 出版商
  78. Vermeulen J, Van Hecke W, Spliet W, Villacorta Hidalgo J, Fisch P, Broekhuizen R, et al. Pediatric Primitive Neuroectodermal Tumors of the Central Nervous System Differentially Express Granzyme Inhibitors. PLoS ONE. 2016;11:e0151465 pubmed 出版商
  79. Seifert L, Werba G, Tiwari S, Giao Ly N, Nguy S, Alothman S, et al. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Gastroenterology. 2016;150:1659-1672.e5 pubmed 出版商
  80. McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-9 pubmed 出版商
  81. Leitch C, Natafji E, Yu C, Abdul Ghaffar S, Madarasingha N, Venables Z, et al. Filaggrin-null mutations are associated with increased maturation markers on Langerhans cells. J Allergy Clin Immunol. 2016;138:482-490.e7 pubmed 出版商
  82. Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Rea D, Barbieri A, et al. A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. J Transl Med. 2016;14:58 pubmed 出版商
  83. Procaccini C, Carbone F, Di Silvestre D, Brambilla F, De Rosa V, Galgani M, et al. The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements. Immunity. 2016;44:406-21 pubmed 出版商
  84. Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38:1074-84 pubmed 出版商
  85. Legorreta Haquet M, Chávez Rueda K, Chávez Sánchez L, Cervera Castillo H, Zenteno Galindo E, Barile Fabris L, et al. Function of Treg Cells Decreased in Patients With Systemic Lupus Erythematosus Due To the Effect of Prolactin. Medicine (Baltimore). 2016;95:e2384 pubmed 出版商
  86. Menter T, Dickenmann M, Juskevicius D, Steiger J, Dirnhofer S, Tzankov A. Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling. Hematol Oncol. 2017;35:187-197 pubmed 出版商
  87. James E, Gates T, LaFond R, Yamamoto S, Ni C, Mai D, et al. Neuroinvasive West Nile Infection Elicits Elevated and Atypically Polarized T Cell Responses That Promote a Pathogenic Outcome. PLoS Pathog. 2016;12:e1005375 pubmed 出版商
  88. Younis R, Han K, Webb T. Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells. J Immunol. 2016;196:1419-29 pubmed 出版商
  89. Kim K, Wen X, Yang H, Kim W, Kang G. Prognostic Implication of M2 Macrophages Are Determined by the Proportional Balance of Tumor Associated Macrophages and Tumor Infiltrating Lymphocytes in Microsatellite-Unstable Gastric Carcinoma. PLoS ONE. 2015;10:e0144192 pubmed 出版商
  90. Günther S, Ostheimer C, Stangl S, Specht H, Mózes P, Jesinghaus M, et al. Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer. Front Immunol. 2015;6:556 pubmed 出版商
  91. Kobayashi S, Watanabe T, Suzuki R, Furu M, Ito H, Ito J, et al. TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur J Immunol. 2016;46:360-71 pubmed 出版商
  92. Vierboom M, Breedveld E, Kap Y, Mary C, Poirier N, t Hart B, et al. Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis. Clin Exp Immunol. 2016;183:405-18 pubmed 出版商
  93. Laborel Préneron E, Bianchi P, Boralevi F, Lehours P, Fraysse F, Morice Picard F, et al. Effects of the Staphylococcus aureus and Staphylococcus epidermidis Secretomes Isolated from the Skin Microbiota of Atopic Children on CD4+ T Cell Activation. PLoS ONE. 2015;10:e0141067 pubmed 出版商
  94. Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16:1235-44 pubmed 出版商
  95. Feng Z, Puri S, Moudgil T, Wood W, Hoyt C, Wang C, et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer. 2015;3:47 pubmed 出版商
  96. Miles B, Miller S, Folkvord J, Kimball A, Chamanian M, Meditz A, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun. 2015;6:8608 pubmed 出版商
  97. Scottà C, Fanelli G, Hoong S, Romano M, Lamperti E, Sukthankar M, et al. Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica. 2016;101:91-100 pubmed 出版商
  98. Zhao L, Li C, Jin P, Ng C, Lin Z, Li Y, et al. Histopathological features of sinonasal inverted papillomas in chinese patients. Laryngoscope. 2016;126:E141-7 pubmed 出版商
  99. Liu K, Yang K, Wu B, Chen H, Chen X, Chen X, et al. Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer. Medicine (Baltimore). 2015;94:e1631 pubmed 出版商
  100. Bézie S, Picarda E, Ossart J, Tesson L, Usal C, Renaudin K, et al. IL-34 is a Treg-specific cytokine and mediates transplant tolerance. J Clin Invest. 2015;125:3952-64 pubmed 出版商
  101. Broos C, van Nimwegen M, Kleinjan A, Ten Berge B, Muskens F, In t Veen J, et al. Impaired survival of regulatory T cells in pulmonary sarcoidosis. Respir Res. 2015;16:108 pubmed 出版商
  102. Gao Y, Zhang M, Li J, Yang M, Liu Y, Guo X, et al. Circulating FoxP3+ Regulatory T and Interleukin17-Producing Th17 Cells Actively Influence HBV Clearance in De Novo Hepatitis B Virus Infected Patients after Orthotopic Liver Transplantation. PLoS ONE. 2015;10:e0137881 pubmed 出版商
  103. Wang W, Yen M, Liu K, Hsu P, Lin M, Chen P, et al. Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses. Stem Cell Reports. 2015;5:392-404 pubmed 出版商
  104. Jasinski Bergner S, Stoehr C, Bukur J, Massa C, Braun J, Hüttelmaier S, et al. Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. Oncoimmunology. 2015;4:e1008805 pubmed
  105. Suradhat S, Wongyanin P, Kesdangsakonwut S, Teankum K, Lumyai M, Triyarach S, et al. A novel DNA vaccine for reduction of PRRSV-induced negative immunomodulatory effects: A proof of concept. Vaccine. 2015;33:3997-4003 pubmed 出版商
  106. Prata T, Bonin C, Ferreira A, Padovani C, Fernandes C, Machado A, et al. Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. Immunology. 2015;146:113-21 pubmed 出版商
  107. Horn T, Laus J, Seitz A, Maurer T, Schmid S, Wolf P, et al. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol. 2016;34:181-7 pubmed 出版商
  108. Castiglioni A, Corna G, Rigamonti E, Basso V, Vezzoli M, Monno A, et al. FOXP3+ T Cells Recruited to Sites of Sterile Skeletal Muscle Injury Regulate the Fate of Satellite Cells and Guide Effective Tissue Regeneration. PLoS ONE. 2015;10:e0128094 pubmed 出版商
  109. McArthur M, Fresnay S, Magder L, Darton T, Jones C, Waddington C, et al. Activation of Salmonella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model. PLoS Pathog. 2015;11:e1004914 pubmed 出版商
  110. Wang Z, Wei M, Zhang H, Chen H, Germana S, Huang C, et al. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo. Mol Oncol. 2015;9:1458-70 pubmed 出版商
  111. Liechtenstein T, Perez Janices N, Blanco Luquin I, Goyvaerts C, Schwarze J, Dufait I, et al. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology. 2014;3:e945378 pubmed
  112. Boer M, Prins C, van Meijgaarden K, van Dissel J, Ottenhoff T, Joosten S. Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults. Clin Vaccine Immunol. 2015;22:778-88 pubmed 出版商
  113. DaFonseca S, Niessl J, Pouvreau S, Wacleche V, Gosselin A, Cleret Buhot A, et al. Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART. Retrovirology. 2015;12:38 pubmed 出版商
  114. Anandasabapathy N, Breton G, Hurley A, Caskey M, Trumpfheller C, Sarma P, et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015;50:924-30 pubmed 出版商
  115. Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520:692-6 pubmed 出版商
  116. Weinberg A, Muresan P, Richardson K, Fenton T, Domínguez T, Bloom A, et al. Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine. PLoS ONE. 2015;10:e0122431 pubmed 出版商
  117. Rochman Y, Yukawa M, Kartashov A, Barski A. Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig. PLoS ONE. 2015;10:e0122198 pubmed 出版商
  118. Punt S, van Vliet M, Spaans V, de Kroon C, Fleuren G, Gorter A, et al. FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma. Cancer Immunol Immunother. 2015;64:745-53 pubmed 出版商
  119. Romani R, Pirisinu I, Calvitti M, Pallotta M, Gargaro M, Bistoni G, et al. Stem cells from human amniotic fluid exert immunoregulatory function via secreted indoleamine 2,3-dioxygenase1. J Cell Mol Med. 2015;19:1593-605 pubmed 出版商
  120. Obiero J, Shekalaghe S, Hermsen C, Mpina M, Bijker E, Roestenberg M, et al. Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection. Infect Immun. 2015;83:2185-96 pubmed 出版商
  121. Bowcutt R, Malter L, Chen L, Wolff M, Robertson I, Rifkin D, et al. Isolation and cytokine analysis of lamina propria lymphocytes from mucosal biopsies of the human colon. J Immunol Methods. 2015;421:27-35 pubmed 出版商
  122. Kim Y, Lim H, Jung H, Wetsel R, Chung Y. Regulation of autoimmune germinal center reactions in lupus-prone BXD2 mice by follicular helper T cells. PLoS ONE. 2015;10:e0120294 pubmed 出版商
  123. Nouël A, Pochard P, Simon Q, Ségalen I, Le Meur Y, Pers J, et al. B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner. J Autoimmun. 2015;59:53-60 pubmed 出版商
  124. Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, et al. The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. Clin Cancer Res. 2015;21:2840-50 pubmed 出版商
  125. Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed 出版商
  126. Hsiao H, Hsu T, Liu W, Hsieh W, Chou T, Wu Y, et al. Deltex1 antagonizes HIF-1α and sustains the stability of regulatory T cells in vivo. Nat Commun. 2015;6:6353 pubmed 出版商
  127. Torres Cabala C, Curry J, Li Ning Tapia E, Ramos C, Tetzlaff M, Prieto V, et al. HTLV-1-associated infective dermatitis demonstrates low frequency of FOXP3-positive T-regulatory lymphocytes. J Dermatol Sci. 2015;77:150-5 pubmed 出版商
  128. Valle A, Barbagiovanni G, Jofra T, Stabilini A, Pérol L, Baeyens A, et al. Heterogeneous CD3 expression levels in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation. J Immunol. 2015;194:2117-27 pubmed 出版商
  129. Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed 出版商
  130. Crncec I, Pathria P, Svinka J, Eferl R. Induction of colorectal cancer in mice and histomorphometric evaluation of tumors. Methods Mol Biol. 2015;1267:145-64 pubmed 出版商
  131. Thomas A, Fisher J, Rahme G, Hampton T, Baron U, Olek S, et al. Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro Oncol. 2015;17:801-9 pubmed 出版商
  132. Engels C, Charehbili A, van de Velde C, Bastiaannet E, Sajet A, Putter H, et al. The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Res Treat. 2015;149:587-96 pubmed 出版商
  133. Däster S, Eppenberger Castori S, Hirt C, Zlobec I, Delko T, Nebiker C, et al. High frequency of CD8 positive lymphocyte infiltration correlates with lack of lymph node involvement in early rectal cancer. Dis Markers. 2014;2014:792183 pubmed 出版商
  134. Vorobjova T, Uibo O, Heilman K, Uibo R. Increased density of tolerogenic dendritic cells in the small bowel mucosa of celiac patients. World J Gastroenterol. 2015;21:439-52 pubmed 出版商
  135. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015;25:208-24 pubmed 出版商
  136. Yu A, Snowhite I, Vendrame F, Rosenzwajg M, Klatzmann D, Pugliese A, et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes. 2015;64:2172-83 pubmed 出版商
  137. Hildebrand A, Jarsch C, Kern Y, Böhringer D, Reinhard T, Schwartzkopff J. Subconjunctivally applied naïve Tregs support corneal graft survival in baby rats. Mol Vis. 2014;20:1749-57 pubmed
  138. Li F, Ji L, Wang W, Hua F, Zhan Y, Zou S, et al. Insufficient secretion of IL-10 by Tregs compromised its control on over-activated CD4+ T effector cells in newly diagnosed adult immune thrombocytopenia patients. Immunol Res. 2015;61:269-80 pubmed 出版商
  139. Hatano R, Ohnuma K, Otsuka H, Komiya E, Taki I, Iwata S, et al. CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway. J Immunol. 2015;194:960-72 pubmed 出版商
  140. Nguyen L, Pan J, Dinh T, Hadeiba H, O Hara E, Ebtikar A, et al. Role and species-specific expression of colon T cell homing receptor GPR15 in colitis. Nat Immunol. 2015;16:207-213 pubmed 出版商
  141. Wu Y, Du Z, Cai Y, Peng W, Zheng G, Zheng G, et al. Effective expansion of forkhead box P3⁺ regulatory T cells via early secreted antigenic target 6 and antigen 85 complex B from Mycobacterium tuberculosis. Mol Med Rep. 2015;11:3134-42 pubmed 出版商
  142. Rutz S, Kayagaki N, Phung Q, Eidenschenk C, Noubade R, Wang X, et al. Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells. Nature. 2015;518:417-21 pubmed 出版商
  143. Kong L, Wei J, Haider A, Liebelt B, Ling X, Conrad C, et al. Therapeutic targets in subependymoma. J Neuroimmunol. 2014;277:168-75 pubmed 出版商
  144. Cousens L, Najafian N, Martin W, De Groot A. Tregitope: Immunomodulation powerhouse. Hum Immunol. 2014;75:1139-46 pubmed 出版商
  145. Rueda C, Wells C, Gisslen T, Jobe A, Kallapur S, Chougnet C. Effect of chorioamnionitis on regulatory T cells in moderate/late preterm neonates. Hum Immunol. 2015;76:65-73 pubmed 出版商
  146. Huss D, Mehta D, Sharma A, You X, Riester K, Sheridan J, et al. In vivo maintenance of human regulatory T cells during CD25 blockade. J Immunol. 2015;194:84-92 pubmed
  147. Willmann K, Klaver S, DoÄŸu F, Santos Valente E, Garncarz W, Bilic I, et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat Commun. 2014;5:5360 pubmed 出版商
  148. Dominguez Villar M, Gautron A, de Marcken M, Keller M, Hafler D. TLR7 induces anergy in human CD4(+) T cells. Nat Immunol. 2015;16:118-28 pubmed 出版商
  149. Thompson I, Mann E, Stokes M, English N, Knight S, Williamson D. Specific activation of dendritic cells enhances clearance of Bacillus anthracis following infection. PLoS ONE. 2014;9:e109720 pubmed 出版商
  150. Hermans C, Anz D, Engel J, Kirchner T, Endres S, Mayr D. Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers. PLoS ONE. 2014;9:e111757 pubmed 出版商
  151. Llosa N, Cruise M, Tam A, Wicks E, Hechenbleikner E, Taube J, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43-51 pubmed 出版商
  152. Thauland T, Koguchi Y, Dustin M, Parker D. CD28-CD80 interactions control regulatory T cell motility and immunological synapse formation. J Immunol. 2014;193:5894-903 pubmed 出版商
  153. Freeman A, Bridge J, Maruthayanar P, Overgaard N, Jung J, Simpson F, et al. Comparative immune phenotypic analysis of cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in immune-competent individuals: proportional representation of CD8+ T-cells but not FoxP3+ Regulatory T-cells is associated with disease stage. PLoS ONE. 2014;9:e110928 pubmed 出版商
  154. Xie L, Choudhury G, Winters A, Yang S, Jin K. Cerebral regulatory T cells restrain microglia/macrophage-mediated inflammatory responses via IL-10. Eur J Immunol. 2015;45:180-91 pubmed 出版商
  155. Weed D, Vella J, Reis I, De La Fuente A, Gomez C, Sargi Z, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:39-48 pubmed 出版商
  156. Bacher P, Kniemeyer O, Teutschbein J, Thön M, Vödisch M, Wartenberg D, et al. Identification of immunogenic antigens from Aspergillus fumigatus by direct multiparameter characterization of specific conventional and regulatory CD4+ T cells. J Immunol. 2014;193:3332-43 pubmed 出版商
  157. Jin J, Zhang W, Wong K, Kwak M, van Driel I, Yu Q. Inhibition of breast cancer resistance protein (ABCG2) in human myeloid dendritic cells induces potent tolerogenic functions during LPS stimulation. PLoS ONE. 2014;9:e104753 pubmed 出版商
  158. Bending D, Pesenacker A, Ursu S, Wu Q, Lom H, Thirugnanabalan B, et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol. 2014;193:2699-708 pubmed 出版商
  159. Zhang X, Gao L, Liang X, Guo M, Wang R, Pan Y, et al. HBV preS2 transactivates FOXP3 expression in malignant hepatocytes. Liver Int. 2015;35:1087-94 pubmed 出版商
  160. Skogberg G, Lundberg V, Lindgren S, Gudmundsdottir J, Sandström K, Kämpe O, et al. Altered expression of autoimmune regulator in infant down syndrome thymus, a possible contributor to an autoimmune phenotype. J Immunol. 2014;193:2187-95 pubmed 出版商
  161. Noyan F, Lee Y, Zimmermann K, Hardtke Wolenski M, Taubert R, Warnecke G, et al. Isolation of human antigen-specific regulatory T cells with high suppressive function. Eur J Immunol. 2014;44:2592-602 pubmed 出版商
  162. Kim K, Chung B, Kim B, Cho M, Yang C. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients. Immunology. 2015;144:68-78 pubmed 出版商
  163. Gupta M, Kolli D, Molteni C, Casola A, Garofalo R. Paramyxovirus infection regulates T cell responses by BDCA-1+ and BDCA-3+ myeloid dendritic cells. PLoS ONE. 2014;9:e99227 pubmed 出版商
  164. Azzimonti B, Zavattaro E, Provasi M, Vidali M, Conca A, Catalano E, et al. Intense Foxp3+ CD25+ regulatory T-cell infiltration is associated with high-grade cutaneous squamous cell carcinoma and counterbalanced by CD8+/Foxp3+ CD25+ ratio. Br J Dermatol. 2015;172:64-73 pubmed 出版商
  165. Jitschin R, Braun M, Büttner M, Dettmer Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750-60 pubmed 出版商
  166. Hodi F, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632-42 pubmed 出版商
  167. Gautron A, Dominguez Villar M, de Marcken M, Hafler D. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur J Immunol. 2014;44:2703-2711 pubmed 出版商
  168. Bedke T, Iannitti R, De Luca A, Giovannini G, Fallarino F, Berges C, et al. Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice. Immunol Cell Biol. 2014;92:659-70 pubmed 出版商
  169. Luciano A, Arbona Ramirez I, Ruiz R, Llorens Bonilla B, Martinez Lopez D, Funderburg N, et al. Alterations in regulatory T cell subpopulations seen in preterm infants. PLoS ONE. 2014;9:e95867 pubmed 出版商
  170. Grage Griebenow E, Jerg E, Gorys A, Wicklein D, Wesch D, Freitag Wolf S, et al. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Mol Oncol. 2014;8:982-97 pubmed 出版商
  171. Kuwahara M, Suzuki J, Tofukuji S, Yamada T, Kanoh M, Matsumoto A, et al. The Menin-Bach2 axis is critical for regulating CD4 T-cell senescence and cytokine homeostasis. Nat Commun. 2014;5:3555 pubmed 出版商
  172. Ito S, Bollard C, Carlsten M, Melenhorst J, Biancotto A, Wang E, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther. 2014;22:1388-1395 pubmed 出版商
  173. Keswani T, Bhattacharyya A. Differential role of T regulatory and Th17 in Swiss mice infected with Plasmodium berghei ANKA and Plasmodium yoelii. Exp Parasitol. 2014;141:82-92 pubmed 出版商
  174. Berney Meyer L, Hung N, Slatter T, Schollum J, Kitching A, Walker R. Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury?. Nephrology (Carlton). 2014;19:359-65 pubmed 出版商
  175. Peguillet I, Milder M, Louis D, Vincent Salomon A, Dorval T, Piperno Neumann S, et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74:2204-16 pubmed 出版商
  176. Sereti I, Estes J, Thompson W, Morcock D, Fischl M, Croughs T, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog. 2014;10:e1003890 pubmed 出版商
  177. Naviglio S, Arrigo S, Martelossi S, Villanacci V, Tommasini A, Loganes C, et al. Severe inflammatory bowel disease associated with congenital alteration of transforming growth factor beta signaling. J Crohns Colitis. 2014;8:770-4 pubmed 出版商
  178. Wolfs T, Kramer B, Thuijls G, Kemp M, Saito M, Willems M, et al. Chorioamnionitis-induced fetal gut injury is mediated by direct gut exposure of inflammatory mediators or by lung inflammation. Am J Physiol Gastrointest Liver Physiol. 2014;306:G382-93 pubmed 出版商
  179. Park S, Veerapu N, Shin E, Biancotto A, McCoy J, Capone S, et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med. 2013;19:1638-42 pubmed 出版商
  180. Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R, et al. Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation. AIDS Res Hum Retroviruses. 2013;29:172-7 pubmed 出版商
  181. Wolff M, Leung J, Davenport M, Poles M, Cho I, Loke P. TH17, TH22 and Treg cells are enriched in the healthy human cecum. PLoS ONE. 2012;7:e41373 pubmed 出版商
  182. Nicholson I, Mavrangelos C, Bird D, Bresatz Atkins S, Eastaff Leung N, Grose R, et al. PI16 is expressed by a subset of human memory Treg with enhanced migration to CCL17 and CCL20. Cell Immunol. 2012;275:12-8 pubmed 出版商
  183. Koreth J, Matsuoka K, Kim H, McDonough S, Bindra B, Alyea E, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055-66 pubmed 出版商
  184. Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R, et al. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol. 2011;85:11422-34 pubmed 出版商
  185. Caramori G, Lasagna L, Casalini A, Adcock I, Casolari P, Contoli M, et al. Immune response to Mycobacterium tuberculosis infection in the parietal pleura of patients with tuberculous pleurisy. PLoS ONE. 2011;6:e22637 pubmed 出版商
  186. Ruffell B, Au A, Rugo H, Esserman L, Hwang E, Coussens L. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012;109:2796-801 pubmed 出版商
  187. West N, Panet Raymond V, Truong P, Alexander C, Babinszky S, Milne K, et al. Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR). Breast Cancer (Auckl). 2011;5:105-15 pubmed 出版商
  188. Gadiot J, Hooijkaas A, Kaiser A, Van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011;117:2192-201 pubmed 出版商
  189. Wu Y, Ren M, Yang R, Liang X, Ma Y, Tang Y, et al. Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th/Treg cell subset imbalance in ankylosing spondylitis. Arthritis Res Ther. 2011;13:R29 pubmed 出版商
  190. Antonelli L, Mahnke Y, Hodge J, Porter B, Barber D, DerSimonian R, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood. 2010;116:3818-27 pubmed 出版商
  191. French J, Weber Z, Fretwell D, Said S, Klopper J, Haugen B. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2325-33 pubmed 出版商
  192. Markley J, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood. 2010;115:3508-19 pubmed 出版商
  193. Oo Y, Weston C, Lalor P, Curbishley S, Withers D, Reynolds G, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol. 2010;184:2886-98 pubmed 出版商
  194. Hunter P, Nistala K, Jina N, Eddaoudi A, Thomson W, Hubank M, et al. Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis Rheum. 2010;62:896-907 pubmed 出版商
  195. Amarnath S, Costanzo C, Mariotti J, Ullman J, Telford W, Kapoor V, et al. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol. 2010;8:e1000302 pubmed 出版商
  196. Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol. 2010;162:1056-63 pubmed 出版商
  197. Houot R, Goldstein M, Kohrt H, Myklebust J, Alizadeh A, Lin J, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood. 2009;114:3431-8 pubmed 出版商
  198. Ellestad K, Tsutsui S, Noorbakhsh F, Warren K, Yong V, Pittman Q, et al. Early life exposure to lipopolysaccharide suppresses experimental autoimmune encephalomyelitis by promoting tolerogenic dendritic cells and regulatory T cells. J Immunol. 2009;183:298-309 pubmed 出版商
  199. Sivasankar B, Longhi M, Gallagher K, Betts G, Morgan B, Godkin A, et al. CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?. J Immunol. 2009;182:5203-7 pubmed 出版商
  200. Milne K, Barnes R, Girardin A, Mawer M, Nesslinger N, Ng A, et al. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS ONE. 2008;3:e3409 pubmed 出版商
  201. Fujimaki W, Takahashi N, Ohnuma K, Nagatsu M, Kurosawa H, Yoshida S, et al. Comparative study of regulatory T cell function of human CD25CD4 T cells from thymocytes, cord blood, and adult peripheral blood. Clin Dev Immunol. 2008;2008:305859 pubmed 出版商
  202. Koenen H, Smeets R, Vink P, van Rijssen E, Boots A, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 2008;112:2340-52 pubmed 出版商
  203. Ebert L, Tan B, Browning J, Svobodova S, Russell S, Kirkpatrick N, et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res. 2008;68:3001-9 pubmed 出版商
  204. Pereira L, Villinger F, Wulff H, Sankaranarayanan A, Raman G, Ansari A. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med (Maywood). 2007;232:1338-54 pubmed
  205. Kang S, Lim H, Andrisani O, Broxmeyer H, Kim C. Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol. 2007;179:3724-33 pubmed
  206. Yates J, Rovis F, Mitchell P, Afzali B, Tsang J, Garin M, et al. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol. 2007;19:785-99 pubmed
  207. Zuber J, Viguier M, Lemaitre F, Senée V, Patey N, Elain G, et al. Severe FOXP3+ and naïve T lymphopenia in a non-IPEX form of autoimmune enteropathy combined with an immunodeficiency. Gastroenterology. 2007;132:1694-704 pubmed
  208. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225-32 pubmed
  209. Yu Q, Saruta M, Avanesyan A, Fleshner P, Banham A, Papadakis K. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis. 2007;13:191-9 pubmed
  210. Lim H, Broxmeyer H, Kim C. Regulation of trafficking receptor expression in human forkhead box P3+ regulatory T cells. J Immunol. 2006;177:840-51 pubmed